Quantitative proteomic analysis of follicular lymphoma cells in response to rituximab.
Rituximab is a monoclonal antibody that targets the uniquely expressed B-cell CD20 receptor. Although recently approved for treatment of follicular lymphomas, the intracellular events that occur when rituximab binds to CD20 are largely unknown. Quantitative proteomic analysis of B-cell lymphoma-derived cells exposed to rituximab was performed. Differentially expressed proteins belonged to functional groups involved in migration, adhesion, calcium-induced signaling, ubiquitination, and components of the phosphoinositol and NF-kappaB pathways. Our studies reveal the proteomic consequences of rituximab treatment and provide novel insights into the mechanism of action of the drug in susceptible B-cell lymphoproliferative disorders.
Everton
Kathryn L
KL
Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA.
Abbott
David R
DR
Crockett
David K
DK
Elenitoba-Johnson
Kojo S J
KS
Lim
Megan S
MS
D000595:Amino Acid Sequence; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000494:pharmacology*; D015153:Blotting, Western; D053148:Caspase 3 / Q000096:biosynthesis / Q000378:metabolism; D002853:Chromatography, Liquid; D030562:Databases, Protein; D004790:Enzyme Induction; D005434:Flow Cytometry; D006801:Humans; D008224:Lymphoma, Follicular / Q000378:metabolism* / Q000473:pathology; D008969:Molecular Sequence Data; D009363:Neoplasm Proteins / Q000378:metabolism*; D040901:Proteomics; D000069283:Rituximab; D053719:Tandem Mass Spectrometry; D014407:Tumor Cells, Cultured
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D000069283:Rituximab; D053148:Caspase 3